Featured Post
Respirology | APSR Respiratory Medicine Journal
Taiwan's Lung Cancer Mortality Rate Drops
By Lee I-chia / Staff reporter
The mortality rate of lung cancer in Taiwan has declined for nine consecutive years, with early detection through screening the key to significantly improving survival rates, the Health Promotion Administration (HPA) said yesterday.
Lung cancer is the leading cause of cancer-related deaths worldwide, WHO data showed.
Nearly 2.5 million people were diagnosed with lung cancer in 2022 and more than 1.8 million people died from the disease, International Agency for Research on Cancer data showed.
Photo courtesy of Changhua Christian Hospital
In Taiwan, the standardized mortality rate of lung cancer has declined for nine consecutive years, although the disease still killed 10,348 people last year and it is the leading cause of cancer-related deaths in the nation, the HPA said.
The case fatality rate is relatively high, but it varies significantly based on the stage at diagnosis, it said.
In 2022, 6.2 percent of people with the disease were diagnosed at stage 0, 32.3 percent at stage 1, 3.7 percent at stage 2, 10.4 percent at stage 3 and 47.7 percent at stage 4, HPA data showed.
The five-year survival rate at stage 1 is about 90 percent, but it drops to nearly 60 percent at stage 2, nearly 30 percent at stage 3 and only about 10 percent at stage 4, showing a significant difference between early and late detection, the agency said.
Detecting lung cancer early is key to increasing survival rates, it said.
The HPA said it has expanded eligibility for government-funded low-dose computed tomography (LDCT) lung cancer screenings this year based on the recommendation of the US Preventive Services Task Force's recommendation that heavy smokers undergo the screenings, as well as the results of a domestic study titled "Taiwan Lung Cancer Screening In Never-smoker Trial."
With the expanded criteria, people who meet one of two high-risk criteria are eligible for a LDCT every two years, the HPA said.
The two criteria are: men aged 45 to 74 and women aged 40 to 74 who have a family history of lung cancer — meaning that a biological parent, sibling or child has been diagnosed with lung cancer; and adults aged 50 to 74 who are heavy smokers or were heavy smokers, but have not smoked for 15 years or less.
The HPA defines a "heavy smoker" as someone with a smoking history of at least 20 "pack-years," ie, when packs of cigarettes per day and years of smoking are multiplied, it gives 20. For example, more than one pack per day for 20 years or half a pack per day for 40 years.
HPA Director-General Wu Chao-chun (吳昭軍) said that LDCT can detect early lung cancer, but it cannot reduce incidence rates, so the best prevention is to quit smoking.
Studies suggest that smokers can reduce their risk of lung cancer by 50 percent if they have quit smoking for 10 to 15 years, Wu said.
AstraZeneca Backs AI To Accelerate Lung Cancer Screening, Shares Evidence On Impact In Resource-limited Settings
Read by: 100 Industry Professionals
Presenting the study findings at the European Lung Cancer Congress (ELCC) 2025, the UK-based MNC drug giant AstraZeneca stated that artificial intelligence (AI) has the potential to "improve lung cancer risk detection, especially within resource-limited healthcare settings."
Adding to this, Iskra Reic, Executive Vice President (EVP), International, AstraZeneca, said, "To transform patient care and with the aim of eliminating cancer as a cause of death, we must address the significant and disproportionate burden in low-and-middle-income countries and resource-limited settings through tailored and scalable solutions.""Innovation in healthcare is crucial for transforming patient outcomes. By leveraging AI technology for lung cancer detection, especially in resource-limited settings, we aim to enhance early diagnosis and ultimately improve survival rates," said Sanjeev Panchal, Country President and Managing Director, AstraZeneca India Pharma.
Under the study, AstraZeneca utilised the qXR-LNMS tool from Qure.AI to provide real-world data to predict the risk of malignancy of incidental pulmonary nodules on a chest X-ray, compared to a radiologist's assessment using the gold standard imaging modality, low-dose CT scan.As per the company release, lung cancer is the leading cause of cancer-related deaths worldwide, and in India, it is the fourth leading cause of cancer-related death.
qXR-LNMS uses AI to automatically detect lung nodules and lymph node metastasis, whereas under the current diagnostic approach, radiologists manually analyze and interpret chest X-rays.
Subscribe to our newsletter to get latest insights & analysis.
WVU Cancer Institute's LUCAS Mobile Screening Unit To Stop In Mercer County On April 29
Viber
Princeton, WV (WOAY)—WVU Cancer Institute's Lucas (Lung Cancer Screening)Mobile Lung Cancer Screening Unit will visit Mercer County at the end of the month to offer low-dose computed tomography (LDCT) scans.
The unit will be in Princeton on Tuesday, April 29, from 8:00 am to 4:00 pm at the Bluestone Health Center.
LUCAS lung cancer screenings are billed to private insurance, Medicaid, or Medicare.
However, uninsured patients living in West Virginia who meet screening criteria can also receive their lung cancer screening on LUCAS through grant funding and donations.
Patients must have a physician's order and prior authorization from insurance to get screened.
Appointments must be made 14 or more days before the visit to allow time for pre-authorizations for insurance.
In the Montain State, more people die of lung cancer than colorectal, prostate, and breast cancer combined.
The mobile unit travels to the 42 counties in the state without easy access to lung cancer screening.
To schedule an appointment, call (304)431-5499.
For more information about the LUCAS unit, visit wvucancer.Org/LUCAS.
Related
Sponsored Content
Viber

Comments
Post a Comment